Carrier-free nanomedicines self-assembled from palbociclib dimers and Ce6 for enhanced combined chemo-photodynamic therapy of breast cancer

Palbociclib is the world's first CDK4/6 kinase inhibitor to be marketed. However, it is not effective in the treatment of triple negative breast cancer (TNBC) due to the loss of retinoblastoma protein expression. Thus, combinatorial chemotherapy is indispensable for TNBC treatment. Herein, a ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zheng, Hu, Huaisong, Xian, Tong, Xu, Zhigang, Tang, Dianyong, Wang, Bochu, Zhang, Yimei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827281/
https://www.ncbi.nlm.nih.gov/pubmed/36688062
http://dx.doi.org/10.1039/d2ra05932k

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827281/
https://www.ncbi.nlm.nih.gov/pubmed/36688062
http://dx.doi.org/10.1039/d2ra05932k

Ejemplares similares